US Pharma MarketingMerck, Kelun score with sac-TMT in endometrial cancer trial
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). Merck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 trial of certain patients with endometrial cancer, the companies are taking steps to gain clearance of sac-TMT in another indication. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and…
Merck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 trial of certain patients with endometrial cancer, the companies are taking steps to gain clearance of sac-TMT in another indication.
Source: FiercePharma